Introduction
============

Aniridia (OMIM [106210](http://www.ncbi.nlm.nih.gov/omim/106210)) is a congenital eye disorder characterized by the complete or partial absence of the iris and iris hypoplasia. Eight-five percent of individuals with aniridia inherit this disorder as an autosomal-dominant trait, 13% occur as part of the autosomal-dominant WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), and the remaining 2% occur as part of other disorders, including Peters' anomaly and Gillespie's syndrome, in either autosomal-dominant or autosomal-recessive inheritances \[[@r1]-[@r3]\].

The paired box gene 6 (*PAX6*) is located on chromosome 11p13 and contains 14 exons encoding a protein (PAX6) with 422 amino acids. PAX6 is a transcriptional factor controlling development of a diversity of organs and tissues (forebrain, pancreas, and ocular tissues, including corneal epithelium, lens, and retina) by recognizing specific DNA sequences of its downstream target genes \[[@r4]\]. Nonsense mutations or deletions of the *PAX6* gene primarily cause aniridia due to its haplo-insufficiency \[[@r5]\], while missense mutations of this gene are associated with a diversity of eye abnormalities through gain-of-function of the mutated protein, such as Peters' anomaly, corneal dystrophy and opacification, congenital cataracts, glaucoma, and foveal hypoplasia \[[@r2],[@r6],[@r7]\]. Whereas mutations or intragenic deletions of *PAX6* represent the major causes of aniridia, genomic rearrangements involving the downstream region of *PAX6* were identified in patients with aniridia although both copies of *PAX6* are intact in these patients \[[@r8]-[@r13]\].

In the present study, we report a genomic microdeletion in the downstream region of *PAX6* in a large Chinese family with familial aniridia and other eye anomalies, using microarray-based comparative genomic hybridization (aCGH) techniques. To our knowledge this is the first case found in an Asian population and is one of few similar cases with this kind of genetic mechanism \[[@r9],[@r11],[@r12]\].

Methods
=======

Patients
--------

A five-generation Chinese family with familial aniridia was recruited from Heilongjiang province, northeastern China. There were 15 affected individuals in this family from which five affected members (II:2, III:4, III:6, III:13, and IV:11) and one unaffected individual (IV:4) participated in this study ([Figure 1](#f1){ref-type="fig"}). Ocular tests for these six members included visual acuity of naked eyes and corrected visual acuity, which were recorded using the logarithm of the minimum angle of resolution E chart (Precision Vision, Villa Park, IL), slit-lamp biomicroscopy, measurement of intraocular pressure by applanation tonometry, and gonioscopic evaluation of the anterior chamber angle. Systemic evaluation was performed in the six subjects in this study to exclude WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Axenfeld--Rieger syndrome, iridocorneal endothelial syndromes, sclerocornea, and Peter's anomaly. Informed consents were obtained from the six individuals in this study. Five affected patients and one family member with normal phenotype were further investigated using molecular techniques. The research protocol for this study was approved by the Harbin Medical University Ethics Committee (Harbin, China).

![Pedigree of the family in this study. Squares and circles indicated males and females respectively. The symbols in black represent the affected members. The asterisks indicate those subjects who participated in this study. The arrow indicates the proband. The square with a line indicated a deceased individual.](mv-v17-448-f1){#f1}

Experiments
-----------

All exons of *PAX6* in the proband (III:4) were amplified and sequenced with the ABI BigDye Terminator Cycle Sequencing kit v3.1, (ABI Applied Biosystems, Foster City, CA) according to the described protocol \[[@r14]\]. The superimposed mutant PCR products were subcloned into pGEM-T vector (Promega, Madison, WI) and sequenced to identify the mutation. The genomic DNA from the proband was analyzed by aCGH using the Agilent Human Genome Microarray Kit 244K (Agilent Technologies, Santa Clara, CA) based on the published procedures \[[@r15]\]. The digested test DNA and reference DNA were labeled with cyanine (Cy)3-deoxyuridine triphosphate (dUTP) or Cy5-dUTP, respectively. Following purification, the appropriate Cy3-labeled test DNA and Cy5-labeled reference DNA were mixed together and combined with 2× Hybridization buffer (Agilent), 10× blocking agent (Agilent), and Human Cot-1 DNA (Invitrogen, Carlsbad, CA). The hybridization mixture was slowly dispensed to a microarray chip and assembled with an Agilent SureHyb chamber. After washing, all microarray slides were scanned on an Agilent Microarray Scanner G2565BA with 5-μm resolution. Captured images were transformed to data with Feature Extraction Software, version 9.5 (Agilent), and then imported into Agilent CGH Analytics 3.2.5 software for analysis. Quantitative real-time PCR (qPCR) was performed to verify the abnormal aCGH findings in the proband and to test other family members, according to published guidelines \[[@r16]\]. Individual optimization qPCRs were performed in a 20 μl volume including 25 ng template DNA, 200 nM of each primer, and 1× Premix-Choice with ROX reference dye in an initial denaturation of 93 °C for 10min, followed by 35 cycles of 93 °C for 1 min and 61 °C for 1 min, and 72 °C for 1 min. The three sets of primers for qPCR analysis ([Table 1](#t1){ref-type="table"}) include primers targeted to the elongation factor protein 4 *(ELP4)* gene within the deleted genomic region, primers within the *PAX6* gene, and reference primers within the Oral-facial-digital syndrome 1 protein *(OFD1)* gene on the human X chromosome. Both *ELP4* and *PAX6* were assayed as test genes compared with *OFD1*, and both *ELP4* and *PAX6* were assayed as test/controls.

###### Primer information.

  **Primer sets**     **Primers sequences**               **Amplified region**       **Amplicon size**   **Target genes**
  ------------------- ----------------------------------- -------------------------- ------------------- ------------------
  Target primers      Forward: aatgtttcggcctacgatgggagt   chr11:31586811--31586956   146 bp              *FOXC2*
  ** **               Reverse: tttagcacccacttacccttccca   ** **                      ** **               ** **
  Target primers      Forward: tcataaacactgcagccagcctct   chr11:31781362--31781507   146 bp              *PAX6*
  ** **               Reverse: tcccaacactgcagagaccttgaa   ** **                      ** **               ** **
  Reference primers   Forward: aggtgttctgctgctgagatggaa   chrX:13693097--13693233    137 bp              *OFD1*
  ** **               Reverse: tccctttgtgcccagatgaagaga   ** **                      ** **               ** **

Results
=======

Clinical findings
-----------------

The clinical findings are summarized in [Table 2](#t2){ref-type="table"}. The proband (III:4), was diagnosed with bilateral iris coloboma, optic atrophy of the left eye, right corneal opacity, and strabismus. Because of glaucoma, the proband had undergone cyclocryotherapy on the left eye in 2002. Other recurrent symptoms in the other affected participants include optic atrophy, retinitis pigmentosa, cataract, subluxation of lens, and dysplasia of trabecular meshwork, fovea, and optic nerve ([Table 2](#t2){ref-type="table"}). Poor vision is due to foveal or optic nerve hypoplasia, cataract, glaucoma and amblyopia. No visible autistic problems or intellectual disabilities were identified in these affected individuals.

###### The clinical findings of individuals in this study.

  ** **    ** **   ** **    **Naked visual acuity**   **IOP (mm Hg)**   ** **   ** **   **Corrected visual acuity with patients' own spectacles**                                       **Anterior chamber angle**                                                                                                                                                                                                     
  -------- ------- -------- ------------------------- ----------------- ------- ------- ----------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- --------- --------- ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------
  II:2     74      female   HM/10cm                   HM/10cm           17      15      bilateral optic atrophy; iris coloboma; retinitis pigmentosa; pannus and aphakia of both eyes   cataract surgery                                                                                          HM/10cm   HM/10cm   dysplasia of trabecular meshwork and closure of the trabecular meshwork by residual iris stump   dysplasia of trabecula r meshwork and closure of the trabecular meshwork by residual iris stump
  III:4    46      male     NLP                       FC/20cm           15      22      optic atrophy of left eye;                                                                      cyclocryotheraphy on the left eye; bilateral iris coloboma, corneal opacity and strabismus of right eye   NLP       0.2       Cannot been seen clearly                                                                         the rudimentary stump of iris and the angle covered by the iris stump
  III:6    43      male     0.04                      0.02              22      19      bilateral cataract, iris coloboma and subluxation of lens;                                      none                                                                                                      0.5       0.4       the rudimentary stump of iris and the angle covered by the iris stump                            the rudimentary stump of iris and the angle covered by the iris stump
  III:13   38      female   0.1                       0.1               18      15      bilateral aniridia; amblyopia;                                                                  none                                                                                                      0.6       0.6       dysplasia of trabecular meshwork                                                                 dysplasia of trabecular meshwork
  IV:4     22      male     1.0                       1.0               16      16      normal                                                                                          none                                                                                                      1.0       1.0       open                                                                                             open
  IV:11    14      female   0.08                      0.1               14      15      bilateral aniridia; amblyopia;                                                                  none                                                                                                      0.6       0.6       the rudimentary stump of iris and the angle covered by the iris stump                            the rudimentary stump of iris and the angle covered by the iris stump

Notes: IOP: intraocular pressure; HM: hand movement; NLP: no light perception; FC: finger count.

Sequencing results for *PAX6*
-----------------------------

All exons of *PAX6* from the six participants of the family were amplified and sequenced using standard techniques. No intragenic point mutation or deletion could be identified (data not shown).

Microarray-based comparative genomic hybridization findings in the proband
--------------------------------------------------------------------------

The aCGH analysis detected 35 copy number variations (CNVs) in the proband's genome ([Table 3](#t3){ref-type="table"}). One of them is a 566 kb hemizygous deletion of chromosome 11p13 (chr:31,074,403--31,640,263) with approximately a 123 kb distance from the 3′ end of *PAX6* (chr11:31,762,916--31,796,085) according to HG18 ([NCBI](http://www.ncbi.nlm.nih.gov/pubmed) 36, March 2006; [Figure 2](#f2){ref-type="fig"}. This deletion contains four annotated genes: doublecortin domain containing 1 (*DCDC1*), DnaJ homolog subfamily C member 24 (*DNAJC24*), IMP1 inner mitochondrial membrane (*IMMP1L*), and elongation factor protein 4 (*ELP4*). The remaining 34 CNVs were considered to be benign because these CNVs were identified in healthy individuals documented in the [Database](http://projects.tcag.ca/variation) of Genomic Variation or in recent publications \[[@r17],[@r18]\].

###### Total CNVs identified in the genome of this individual.

  **Number**   **Chromosome**   **Cytoband**      **Start**   **Stop**    **Size**   **Duplication**   **Deletion**   **Gene names**
  ------------ ---------------- ----------------- ----------- ----------- ---------- ----------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------
  1            chr1             q21.3             150822873   150848709   25836      2.044245          0              *LCE3C*
  2            chr3             p12.3             75895820    75958100    62280      0                 −0.682351      *ZNF717*
  3            chr3             q26.1             164038717   164101976   63259      0                 −0.921074       
  4            chr3             q29               196943180   196950295   7115       0                 −0.784749      *MUC20, MUC20*
  5            chr4             q13.2             69057535    69166014    108479     0                 −4.405964      *UGT2B17*
  6            chr4             q28.3             131700605   131865354   164749     0                 −0.598187      * *
  7            chr5             p15.33            802318      878490      76172      0.667749          0              *ZDHHC11*
  8            chr5             q13.2             69741118    70422497    681379     0                 −1.028287      *GTF2H2C, GTF2H2B, GTF2H2D, SERF1A, SERF1A, SERF1B, SMN1, SMN2, SMN1, SMN2, NAIP, GTF2H2B, GTF2H2C, GTF2H2, GTF2H2D, OCLN, LOC647859*
  9            chr6             p22.1             29201691    29260945    59254      0                 −1.115529      *OR2J2*
  10           chr6             p21.32            32567182    32660290    93108      0                 −2.059653      *HLA-DRB5, HLA-DRB6, HLA-DRB1*
  11           chr6             p21.32            32595202    32605500    10298      0                 −4.758382      *HLA-DRB5*
  12           chr6             p12.1             55468168    55501199    33031      0                 −0.627628      *HMGCLL1*
  13           chr7             p22.3             140013      225040      85027      0.843971          0              * *
  14           chr7             q21.2             92484285    92530356    46071      0                 −0.870801      * *
  15           chr7             q32.3 - q33       132382438   132457449   75011      0                 −1.214264      *CHCHD3*
  16           chr7             q34               141413152   141438704   25552      1.057004          0              *MGAM*
  17           chr7             q34               142158954   142171818   12864      0                 −2.550414      *TRY6*
  18           chr8             p11.23 - p11.22   39356395    39505456    149061     1.698241          0              *ADAM5P, ADAM3A*
  19           chr11            p13               31074403    31640263    565860     0                 −1.081172      *DCDC1, DNAJC24, IMMP1L, ELP4*
  20           chr11            q11               55124530    55195190    70660      0                 −0.554403      *OR4C11, OR4P4, OR4S2, OR4C6*
  21           chr12            p13.31            9528390     9585356     56966      1.893183          0              * *
  22           chr14            q32.33            105602556   105630289   27733      0                 −3.599436      * *
  23           chr14            q32.33            105962105   105985658   23553      0.992122          0              * *
  24           chr15            q11.2             18809804    18884636    74832      0.536094          0              * *
  25           chr15            q11.2             19845742    20080135    234393     0.435061          0              *LOC727924, OR4M2, OR4N4, LOC650137*
  26           chr16            p13.3             2638381     2672274     33893      0.722366          0              
  27           chr16            p13.11            14955977    15023221    67244      0                 −0.94928       *PDXDC1*
  28           chr16            q12.2             54354443    54380034    25591      0                 −0.650633      *CES4*
  29           chr16            q22.1             68706040    68754434    48394      0                 −0.495966      *PDPR*
  30           chr17            q21.31 - q21.32   41553026    42049740    496714     0                 −0.347977      *KIAA1267, LRRC37A, ARL17, ARL17, LRRC37A2, ARL17P1, ARL17P1, ARL17, NSF*
  31           chr17            q25.3             77422498    77503885    81387      0.905508          0              *ARHGDIA, THOC4, ANAPC11, ANAPC11, NPB, PCYT2, SIRT7, MAFG, MAFG, LOC92659, PYCR1, PYCR1, MYADML2, NOTUM*
  32           chr19            p12               20422376    20493601    71225      0                 −0.809494      
  33           chr20            p13               1516766     1539355     22589      0                 −1.330169      *SIRPB1, SIRPB1*
  34           chr22            q12.3             35217849    35225862    8013       0.921708          0              *FOXRED2, FOXRED2*
  35           chr22            q13.1             37688858    37715585    26727      0                 −0.689394      *APOBEC3A, APOBEC3B*

![The 556 kb genomic deletion of chromosome 11p13. This deletion harbors four annotated genes, *DCDC1, DNAJC24, IMMP1L*, and *ELP4*.](mv-v17-448-f2){#f2}

Quantitative real-time PCR assays in the proband and other family members
-------------------------------------------------------------------------

The 566 kb hemizygous deletion of chromosome 11p13 in the proband was verified by qPCR using primers targeted to *ELP* within the deleted region, which showed one threshold cycle difference between the patient and reference DNA samples for the amplification of the test gene ([Figure 3](#f3){ref-type="fig"}). Two copies of *PAX6* were confirmed by qPCR, consistent with the aCGH results in this individual (data not shown). We used the qPCR method for testing the other five family members in a blind fashion, four affected family members with eye anomalies, and one healthy individual. All four patients were confirmed to carry the deletion, including *ELP*, but not *PAX6*. The phenotypic normal individual showed two copies for both *ELP* and *PAX6* (data not shown).

![qPCR analysis result. An example of the qPCR amplification plot showed a single copy of the test gene, *ELP4*, in the affected individuals compared to the two copies of this gene in the reference DNA.](mv-v17-448-f3){#f3}

Discussion
==========

The major finding in this Chinese family with familial aniridia is the presence of a 566 kb heterozygous deletion containing four annotated genes: *DCDC1, DNAJC24, IMMP1L,* and *ELP4*. The proximal breakpoint of this deletion is approximately 123 kb from the 3′ end of *PAX6*. We postulate that this 566 kb heterozygous deletion is the underlying cause of the familial aniridia and acts by disrupting the transcription in one of the two PAX6 alleles, even though the two copies of *PAX6* were intact in all individuals investigated in this study.

Our finding provides further evidence of the existence of the remote 3′ regulatory elements in the downstream region of *PAX6* controlling the expression of this gene, if disrupted, leading to aniridia and other eye anomalies. To our knowledge, this is the first case found in Asian patients with aniridia and one of few similar cases with this kind of genetic mechanism.

Our postulation is based on following evidence: 1) The heterozygous deletion segregated with aniridia in the five affected individuals but not in the unaffected individual, while the exons and splicing regions of *PAX6* are apparently free of mutations. 2) Several publications reported similar observations in patients with aniridia, but the chromosomal breakpoint from the 3′ end of *PAX6* and the fragment of deletion were different. For example, two aniridia pedigrees have been characterized in which the disease segregates with chromosomal re-arrangements that involve 11p13 but do not disrupt the *PAX6* gene since the chromosomal breakpoint is at least 85 kb away from the 3′ end of *PAX6* \[[@r8]\]. Two aniridia pedigrees have also been described in which deletion in the *ELP4* gene region, not involving *PAX6*, was present in all subjects with aniridia but not in the investigated normal relatives \[[@r12]\]. A 1.3 Mb deletion (including seven annotated genes^:^ metallophosphoesterase domain containing 2 (*MPPED2*), doublecortin domain containing 5 (*DCDC5*), *DCDC1*, *DNAJC24, IMMP1L,* zinc finger CLS domain containing 3 (*DPH4*), and *ELP4*) has been characterized that starts 35 kb from the 3′ end of *PAX6* in a patient with aniridia, autism, and mental retardation \[[@r11]\]. Recently a \~406 kb heterozygous genomic deletion containing four annotated genes (*DCDC1, DNAJC24, IMMP1L,* and *ELP4*) was found in patients with aniridia \[[@r13]\]; apparently the gene contents in this deletion are the same as the 566 kb heterozygous deletion in the family we report here. 3) Functional studies in both human cells and animal models confirmed the existence of remote 3′ regulatory elements in the downstream region of *PAX6*. Deletions in this region have been shown to abolish PAX6 expression and cause aniridia and other eye anomalies due to loss of enhancers and a downstream regulatory region \[[@r9],[@r19],[@r20]\].

Little information is known about the four annotated genes within the 566 kb deletion in this study. It is also unknown whether these genes are involved in any of the phenotypic features found in these individuals carrying the deletion. The *DCDC1* gene encodes a member of the doublecortin family, which is highly expressed in testis and fetal brain \[[@r21]\]. *DNAJC24* is one of several enzymes involved in synthesis of diphthamide, which is a unique posttranslationally modified histidine found only in translation elongation factor 2 \[[@r22]\]. *IMMP1L* encodes a peptidase similar to mitochondrial inner membrane peptidase (IMP1), which is one of the catalytic subunits of the IMP complex proteolytically removing the mitochondrial targeting presequence of nuclear-encoded proteins \[[@r23]\]. *ELP4* encodes a component of the six subunit elongator complex, a histone acetyltransferase complex that associates directly with RNA polymerase II during transcriptional elongation. Two recent reports indicate that *ELP4* is possibly associated with the centrotemporal sharp wave electroencephalogram (EEG) trait in rolandic epilepsy and speech sound disorder \[[@r24],[@r25]\].

Submicroscopic copy number variations may play a role in human diseases either by loss of gene expression regulatory elements or by disrupting coding sequences. As well as the point mutations in *PAX6* exons, copy number variation should be investigated in the ﬂanking regions of *PAX6*. We suggest that patients, such as the subjects reported here, should be investigated using high resolution aCGH techniques in a clinical setting if sequencing analyses for *PAX6* in patients with aniridia is negative.
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